MAT2A: Potential Drug Target and Biomarker for Various Diseases

Target Name: MAT2A

NCBI ID: G4144

MAT2A

MAT2A: Potential Drug Target and Biomarker for Various Diseases

MAT2A (AdoMet synthetase 2) is a gene that encodes a protein known as adenosine monophosphate synthetase 2. This protein is a key enzyme in the adenosine biosynthesis pathway, which is involved in the regulation of various cellular processes, including cell signaling, inflammation, and stress responses.

Recent studies have identified MAT2A as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. This is due to MAT2A's involvement in the production of adenosine, which has been shown to have immunosuppressive and anti-inflammatory effects.

Adenosine is a naturally occurring molecule that plays a crucial role in the immune system. When the body is under stress or is fighting off an infection, adenosine is produced to help protect the body from harm. However, in diseases such as cancer and neurodegenerative diseases, the production of adenosine is disrupted, leading to an imbalance in the immune system that can contribute to the development and progression of these diseases.

MAT2A is a key enzyme in the adenosine biosynthesis pathway, which is involved in the production of adenosine from the amino acid arginine. MAT2A is a critical enzyme in this pathway, as it catalyzes the conversion of arginine to adenosine. This conversion is the first step in the production of adenosine, and MAT2A plays a crucial role in regulating the rate at which adenosine is produced.

MAT2A is also involved in the regulation of the levels of adenosine in the body. Studies have shown that MAT2A can regulate the amount of adenosine that is produced and can also affect the levels of adenosine in the body. This regulation is important for maintaining a balance in the immune system and for preventing the production of excessive levels of adenosine that can be harmful to the body.

In addition to its role in the immune system, MAT2A has also been shown to have other physiological functions. For example, MAT2A has been shown to play a role in the regulation of cell signaling, and it has been shown to affect the production of various signaling molecules that are involved in cell signaling. MAT2A has also been shown to be involved in the regulation of cell division and in the regulation of DNA replication.

MAT2A has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Studies have shown that MAT2A is often expressed at higher levels in tissues or fluids from patients with these diseases, and that MAT2A has been shown to play a role in the development and progression of these diseases. For example, MAT2A has been shown to be involved in the development of cancer by promoting the production of adenosine, which has been shown to contribute to the development of cancer cells.

In conclusion, MAT2A is a gene that encodes a protein involved in the adenosine biosynthesis pathway. MAT2A has been shown to play a crucial role in the regulation of various cellular processes, including cell signaling, inflammation, and stress responses. In addition, MAT2A has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Further research is needed to fully understand the role of MAT2A in these diseases and to develop effective treatments.

Protein Name: Methionine Adenosyltransferase 2A

Functions: Catalyzes the formation of S-adenosylmethionine from methionine and ATP. The reaction comprises two steps that are both catalyzed by the same enzyme: formation of S-adenosylmethionine (AdoMet) and triphosphate, and subsequent hydrolysis of the triphosphate

The "MAT2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAT2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets